🇺🇸 FDA
Patent

US 12064399

Use of cannabinoids in the treatment of epilepsy

granted A61KA61K31/05A61K31/352

Quick answer

US patent 12064399 (Use of cannabinoids in the treatment of epilepsy) held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/05, A61K31/352, A61K31/5513, A61K31/658